Showing results (41-50 of 65) with videos related to

Sort By:
Pageof 7
Resuscitation|June 20, 2022
Outcomes of in-hospital cardiac arrest among hospitals with and without telemedicine critical careUchenna R Ofoma, Anne M Drewry, Thomas M Maddox, et al.
The Journal of Antimicrobial Chemotherapy|September 13, 2023
Efficacy and safety of ceftazidime/avibactam in patients with infections caused by β-lactamase-producing Gram-negative pathogens: a pooled analysis from the Phase 3 clinical trial programmeAntoni Torres, Michele Wible, Margaret Tawadrous, et al.
Critical Care Explorations|July 8, 2021
Characteristics of U.S. Acute Care Hospitals That Have Implemented Telemedicine Critical CareUchenna R Ofoma, Thomas M Maddox, Chamila Perera, et al.
The Lancet. Infectious Diseases|December 20, 2017
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trialAntoni Torres, Nanshan Zhong, Jan Pachl, et al.
Intensive Care Medicine|November 11, 2020
Pulmonary infections complicating ARDSCharles-Edouard Luyt, Lila Bouadma, Andrew Conway Morris, et al.
The Lancet. Infectious Diseases|October 15, 2020
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trialRichard G Wunderink, Yuko Matsunaga, Mari Ariyasu, et al.
Open Forum Infectious Diseases|September 29, 2025
Rezafungin Versus Caspofungin for the Treatment of Candidemia and Invasive Candidiasis: Results from the Double-blind, Randomized, Phase 3 ReSTORE Trial Including the China Extension StudyGeorge R Thompson, Haihui Huang, Sizhou Feng, et al.
Antimicrobial Agents and Chemotherapy|December 5, 2018
A Hypothesis-Generating Study of the Combination of Aspirin plus Macrolides in Patients with Severe Community-Acquired PneumoniaMarco Falcone, Alessandro Russo, Yuichiro Shindo, et al.
Critical Care (London, England)|October 29, 2024
Rezafungin versus caspofungin for patients with candidaemia or invasive candidiasis in the intensive care unit: pooled analyses of the ReSTORE and STRIVE randomised trialsPatrick M Honoré, Massimo Girardis, Marin Kollef, et al.
Lancet (London, England)|November 28, 2022
Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis (ReSTORE): a multicentre, double-blind, double-dummy, randomised phase 3 trialGeorge R Thompson, Alex Soriano, Oliver A Cornely, et al.
Pageof 7